{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:39:00Z","timestamp":1740166740266,"version":"3.37.3"},"reference-count":49,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.2217\/nmt-2020-0059","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T08:04:41Z","timestamp":1612166681000},"page":"99-111","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["CLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tablets in Suboptimally Controlled Relapsing Multiple Sclerosis"],"prefix":"10.1080","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-6932","authenticated-orcid":false,"given":"Augusto A","family":"Miravalle","sequence":"first","affiliation":[{"name":"Advanced Neurology of Colorado University of Colorado\rFort Collins\rCO\r80528\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-7854","authenticated-orcid":false,"given":"Joshua","family":"Katz","sequence":"additional","affiliation":[{"name":"Elliot Lewis Center for Multiple Sclerosis Care Wellesley\rMA\r02481\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-0981","authenticated-orcid":false,"given":"Derrick","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Neurology Multiple Sclerosis Division University of South Florida\rTampa\rFL\r33612\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-7445","authenticated-orcid":false,"given":"Brooke","family":"Hayward","sequence":"additional","affiliation":[{"name":"EMD Serono Inc. Rockland\rMA\r02370\rUSA an affiliate of Merck KGaA\rDarmstadt\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1273-4768","authenticated-orcid":false,"given":"Danielle E","family":"Harlow","sequence":"additional","affiliation":[{"name":"EMD Serono Inc. Rockland\rMA\r02370\rUSA an affiliate of Merck KGaA\rDarmstadt\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A","family":"Lebson","sequence":"additional","affiliation":[{"name":"EMD Serono Inc. Rockland\rMA\r02370\rUSA an affiliate of Merck KGaA\rDarmstadt\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-3031","authenticated-orcid":false,"given":"Jacob A","family":"Sloane","sequence":"additional","affiliation":[{"name":"BIDMC Department of Neurology Harvard Medical School\rBoston\rMA\r02115\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann D","family":"Bass","sequence":"additional","affiliation":[{"name":"Neurology Center of San Antonio\rSan Antonio\rTX\r78258\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J","family":"Fox","sequence":"additional","affiliation":[{"name":"Central Texas Neurology Consultants\rRound Rock\rTX\r78681\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,2]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1517-1"},{"key":"e_1_3_4_4_1","unstructured":"National Multiple Sclerosis Society . Definition of MS. www.nationalmssociety.org\/What-is-MS\/Definition-of-MS"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30443-5"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007035"},{"key":"e_1_3_4_7_1","unstructured":"National Multiple Sclerosis Society . Relapsing-remitting MS (RRMS). www.nationalmssociety.org\/What-is-MS\/Types-of-MS\/Relapsing-remitting-MS"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304333"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(03)00028-2"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3871"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0082-z"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"e_1_3_4_13_1","unstructured":"EMD Serono Inc . Mavenclad package insert. Rockland MA USA (2019)."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.754012"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2011.08.006"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70023-0"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"issue":"8","key":"e_1_3_4_20_1","first-page":"464","article-title":"Real-world evidence: promise and peril for medical product evaluation","volume":"43","author":"Dhruva SS","year":"2018","unstructured":"Dhruva SS , RossJS, DesaiNR. Real-world evidence: promise and peril for medical product evaluation. PT, 43(8), 464\u2013472 (2018).","journal-title":"PT"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520921087"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420922685"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00489"},{"issue":"1","key":"e_1_3_4_24_1","first-page":"200","article-title":"Rationale, design and feasibility assessment of the Phase IV CLASSIC-MS study evaluating long-term efficacy for patients with multiple sclerosis treated with cladribine tablets","volume":"27","author":"Boyko A","year":"2020","unstructured":"Boyko A , CorrealeJ, EdanGet al. Rationale, design and feasibility assessment of the Phase IV CLASSIC-MS study evaluating long-term efficacy for patients with multiple sclerosis treated with cladribine tablets. Eur. J. Neurol, 27(Suppl. 1), 200 (2020).","journal-title":"Eur. J. Neurol"},{"issue":"15","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.94.15_supplement.1487","article-title":"A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis (1487)","volume":"94","author":"De Stefano N","year":"2020","unstructured":"De Stefano N , AchironA, BarkhofFet al. A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis (1487). Neurology, 94(Suppl. 15), 1487 (2020).","journal-title":"Neurology"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-ABN.79"},{"key":"e_1_3_4_27_1","volume-title":"American Academy of Neurology (AAN).","author":"Wu GF","year":"2020","unstructured":"Wu GF , BoschertU, HaywardBet al. CLOCK-MS: evaluating the mechanism of action of cladribine tablets via CNS and blood biomarkers in MS. Presented at: American Academy of Neurology (AAN). (2020) https:\/\/cslide-us.ctimeetingtech.com\/aan2020\/attendee\/eposter\/poster\/2103"},{"key":"e_1_3_4_28_1","unstructured":"ClinicalTrials.gov . Cladribine tablets after treatment with natalizumab (CLADRINA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04178005"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006810"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S115090"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518790390"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.1296"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935019"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419887596"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00729"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1466"},{"issue":"17","key":"e_1_3_4_38_1","first-page":"S24","article-title":"Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life","volume":"74","author":"Miller D","year":"2010","unstructured":"Miller D , RudickRA, HutchinsonM. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology, 74(17 Suppl. 3), S24\u2013S35 (2010).","journal-title":"Neurology"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.017"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418774338"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0220-1"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-96"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516657441"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217319887191"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.3.363"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2015-019"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/427102"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073-13.3.137"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.1687"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2020-0059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:46:44Z","timestamp":1716493604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2020-0059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.2217\/nmt-2020-0059"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2020-0059","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"type":"print","value":"1758-2024"},{"type":"electronic","value":"1758-2032"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}